reported with ABILIFY. NMS can cause hyperpyrexia, muscle rigidity,
diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac
dysrhythmia, and altered mental status. If signs and symptoms appear,
immediate discontinuation is recommended
Tardive dyskinesia (TD)-The risk of developing TD and the potential for it
to become irreversible may increase as the duration of treatment and the
total cumulative dose increase. Prescribing should be consistent with the
need to minimize TD. If signs and symptoms appear, discontinuation should
be considered since TD may remit, partially or completely
Hyperglycemia and diabetes mellitus-Hyperglycemia, in some cases
associated with ketoacidosis, coma, or death, has been reported in
patients treated with atypical antipsychotics including ABILIFY. Patients
with diabetes should be monitored for worsening of glucose control; those
with risk factors for diabetes should undergo baseline and periodic
fasting blood glucose testing. Patients who develop symptoms of
hyperglycemia should also undergo fasting blood glucose testing. There
have been few reports of hyperglycemia with ABILIFY
ABILIFY may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
As with other antipsychotic drugs, ABILIFY should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.
Like other antipsychotics, ABILIFY may have the potential to impair judgment, thinking, or motor skills. Patients should not drive or operate hazardous machinery until they are certain ABILIFY does not affect them adversely.
Disruption of the body's ability to reduce core body temperature has
|SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.|
Copyright©2007 PR Newswire.
All rights reserved